Transplantační medicína

The current status and preventative perspectives

¿Qué aporta Isatuximab al tratamiento del mieloma múltiple? Isatuximab, en sus dos estudios, IKEMA e ICARIA, ha demostrado sólidos beneficios en supervivencia libre de progresión en pacientes en recaída con mieloma múltiple.

¿Qué implican las actualizaciones del estudio IKEMA? La Dra. Nidia Zapata, Subdirectora de Educación médica del INCAN, nos explica, ¿qué implica esto para los pacientes?

Time spent in the glycemic target range and time spent in hypoglycemia are the main CGM metrics that provide a more personalized approach to diabetes management. GV, on the other hand, is a measure of swings in blood glucose levels over hours or days and may contribute to diabetes-related complications.

Time spent in the glycemic target range and time spent in hypoglycemia are the main CGM metrics that provide a more personalized approach to diabetes management. GV, on the other hand, is a measure of swings in blood glucose levels over hours or days and may contribute to diabetes-related complications.